

Consolidated Financial Highlights

17F
First Quarter

EIZ Corporation

6737 August 2017

Changes in Sales Disclosure Information

- "Visual Display Systems" is reclassified into "B&P" (Business & Plus), "Healthcare", "Creative Work", and "V&S" (Vertical & Specific).
- ■EIZO has strengthened its business models transforming into a "Visual Technology Company" that provides total visual solutions. EIZO focuses on markets where customers need highly advanced products and functionality for critical use such as Healthcare, Creative Work and V&S. Sales disclosure information will change to conform with our change in business activity.
- * See details on page 2.

Previous				
\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	B&P			
Visual Display Systems	V&S	Healthcare		
		Creative Work		
		Industry		
Amusement Monitors				
Others				



New
B&P
Healthcare
Creative Work
V&S
Amusement
Other
_



Details of the Market Group

Market Group	Market/Use		
B&P	 Financial institutions Public authorities Educational facilities Office use High end home use 		
Healthcare	Medical imageDiagnostic applicationsOperating room		
Creative Work	Publication / Printing / Photo editingVideo production		
V&S	 Air traffic control Maritime Security & Surveillance Other industrial fields 		
Amusement	LCD-mounted pachinko and slot machines		
Other	Maintenance services and commissioned development of software		



Consolidated Statements of Income


(JPY Million)					_
	16Q1		17Q1		QoQ
	Amount	(%)	Amount	(%)	(%)
Net Sales	16,745	100.0	19,376	100.0	115.7
Cost of Goods Sold	11,781	70.4	13,077	67.5	111.0
Gross Profit	4,963	29.6	6,298	32.5	126.9
Selling, general and administrative expenses	4,105	24.5	4,401	22.7	107.2
Operating Income	858	5.1	1,897	9.8	221.0
Non-operating income/expenses	(389)	(2.3)	642	3.3	-
Ordinary Income	468	2.8	2,540	13.1	541.8
Income before income taxes	468	2.8	2,540	13.1	541.8
Net income attributable to EIZO Corporation's stockholders	296	1.8	1,822	9.4	613.9
Exchange rate: USD	JPY108.04		JPY111.09		102.8
Exchange rate:EUR	JPY121.88		JPY122.26		100.3

Foreign exchange sensitivity (impact on Operating Income due to Yen appreciation) USD JPY90 million (Positive), EUR JPY160 million (Negative)




Note: QoQ = 'Quarter-on-Quarter' growth compared to same quarter previous year.


Main Factors for Changes in Net Sales



Main Factors for Changes in Operating Income




Net Sales: Overall





Net Sales: B&P







FlexScan EV2456 / EV2451

QoQ

■ Total: 95.2%

Overseas: 96.2%

Sales decreased due to the effects of new product launches in the previous quarter despite a good sales momentum of frameless monitors in Europe and North America.


■ Japan: 92.3%

Sales decreased due to the effect of new product launches in the previous quarter.



Net Sales: Healthcare







QoQ

■ Total: 121.2%

Overseas: 125.5%

Sales increased due to the increasing sales of endoscopy monitors, and diagnostic monitors in Europe and North America.


■ Japan: 115.9%

Sales increased due to the good momentum of the system integration business.



Net Sales: Creative Work

(JPY Billion) Japan Overseas





QoQ

■ Total: 107.0%

Overseas: 114.6%

Sales increased due to the sales of new products for professional users in Europe and North America.


Japan: 84.5%

Sales decreased due to a decrease in sales for entry-level users.



Net Sales: V&S

(JPY Billion) Japan Overseas





QoQ

■ Total: 107.2%

Overseas: 101.3%
Sales remained stable.


Japan: 114.7%

Sales increased due to the increase in sales for the financial system in replacement projects.



Net Sales: Amusement

(JPY Billion)





©SANYO BUSSAN CO.,LTD.

QoQ


■ Total: 143.2%

Sales increased due to favorable sales of new products.



Operating Income

(JPY Billion)






■ Total: 221.0%

Operating income increased due to the sales increase in Healthcare and Amusement markets, in addition to cost reduction and improving product mix.



Selling, General and Administrative Expenses


(JPY Billion)





R&D

(JPY Billion)





■ Total: 116.6%

Increased due to prior R&D investment for endoscopy monitors and products complying with MIL Standards.



^{*} Includes manufacturing costs for R&D

Consolidated Balance Sheets

(JPY Million)	16F		17Q1		Difference	
	Amount	(%)	Amount	(%)	Amount	
Cash and equivalents	24,794	21.5	26,609	22.3	1,815	
Notes and accounts receivable	16,973	14.7	15,034	12.6	(1,938)	
Inventories	24,414	21.2	26,567	22.3	2,152	
Other	3,152	2.7	2,695	2.3	(456)	
Current Assets	69,334	60.2	70,907	59.4	1,572	
Tangible Assets	11,771	10.2	11,955	10.0	183	
Other	34,054	29.6	36,492	30.6	2,437 *	
Fixed Assets	45,826	39.8	48,447	40.6	2,621	
Total	115,160	100.0	119,354	100.0	4,194	
Accounts payable	7,694	6.7	7,874	6.6	179	
Other	11,570	10.0	11,697	9.8	127	
Current liabilities	19,264	16.7	19,571	16.4	306	
Long term liabilities	10,614	9.2	11,389	9.5	774	
Shareholders' Equity	85,280	74.1	88,394	74.1	3,113	
Total	115,160	100.0	119,354	100.0	4,194	

[♦] EIZ□®

^{*} Increase in the valuation of investment securities due to market value of shares held

<u>Disclaimer Regarding Forward-looking Statements</u>

Any statements in this document, other than those of historical fact, are forward-looking statements about the future performance of EIZO and its group companies, which are based on management's assumptions and beliefs in light of information currently available, and involve risks and uncertainties. Actual results may differ materially from these forecasts.

Note: "17Q1" appearing in this presentation means "First Quarter Fiscal Year 2017".

http://www.eizo.co.jp

